GlassScriptPhysician profile
Diana Seaders
NPI 1285979138
$3,597.83
in general payments reported to CMS, 2019-2025
34 companies · $948 in 2025
The $948 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $509 · 2023: $850 · 2024: $1,114 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.59 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,413.04 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $262.58 | 2025 | Tagrisso, Enhertu, Lynparza |
| Genentech, INC. | $225.81 | 2023-2024 | Itovebi, Columvi, Polivy |
| Tersera Therapeutics LLC | $159.15 | 2021-2025 | Xermelo, Zoladex |
| Pfizer INC. | $135.63 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $126.19 | 2023-2025 | Imbruvica, Talvey, Tecvayli |
| Kite Pharma, INC. | $121.20 | 2022 | |
| Stemline Therapeutics INC. | $118.00 | 2025 | Orserdu |
| Astellas Pharma US INC | $102.40 | 2023-2024 | Xospata, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $95.70 | 2022 | |
| Merck Sharp & Dohme LLC | $82.78 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $75.49 | 2024-2025 | |
| Glaxosmithkline, LLC. | $70.36 | 2022-2025 | Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $58.94 | 2023-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $56.35 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $48.70 | 2023 | Pomalyst |
| Gilead Sciences, INC. | $41.98 | 2021-2023 | |
| Genentech USA, INC. | $40.71 | 2025 | Venclexta, Polivy |
| Array Biopharma INC | $38.45 | 2025 | Mektovi, Braftovi, Xalkori |
| Springworks Therapeutics, INC. | $36.34 | 2024 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $34.56 | 2022 | |
| Eisai INC. | $33.35 | 2025 | |
| Rigel Pharmaceuticals, INC. | $25.48 | 2022 | |
| Pharmacosmos Therapeutics INC. | $21.92 | 2022 | |
| Kyowa Kirin, INC. | $21.84 | 2022 | |
| Beone Medicines USA, INC. | $21.71 | 2025 | Tevimbra, Brukinsa |
| Daiichi Sankyo INC. | $19.26 | 2024 | Enhertu |
| Adaptive Biotechnologies Corporation | $17.92 | 2023 | Clonoseq |
| Incyte Corporation | $16.72 | 2023 | Jakafi |
| Acrotech Biopharma INC. | $16.15 | 2024 | Beleodaq |
| Seagen INC. | $15.50 | 2023 | Tukysa |
| Coherus Oncology, INC. | $15.46 | 2023 | |
| Aveo Pharmaceuticals, INC. | $14.12 | 2023 | Fotivda |
| Amgen INC. | $14.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Seaders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.